CONFERENCE COVERAGE SERIES
Keystone Symposium: Alzheimer's Disease 2008
Keystone, Colorado
24 – 28 March 2008
Keystone Drug News: CoMentis BACE Inhibitor Debuts
At the Alzheimer’s disease Keystone Symposium, held 24-29 March in Keystone, Colorado, a spate of news on potential future treatments capped a week of presentations...
Keystone Drug News: Agonists for M1, Serotonin Receptors Prime Cholinergic Pump
The cholinergic hypothesis of Alzheimer disease tends to elicit a yawn from scientists who reserve their excitement for anti-amyloid treatments...
Keystone Drug News: Phase 2 Anti-oligomer Sugar Alcohol—How Might It Work?
Eight years ago, JoAnne McLaurin’s research suggested that a particular stereoisomer of a inositol sugar alcohol might make a respectable AD drug...
Keystone Drug News: Glimpse of Lilly’s Phase 1 Passive Vaccine
Antibody therapies for AD have galvanized researchers and affected families and observers from academia, industry, and even the investment community...
Keystone Drug News: Repurposing the Anti-Inflammatory Drug CNI-1493?
To borrow IT-speak, “repurposing” is an underused art in Alzheimer disease drug research...
Keystone Drug News: Pyroglu Aβ—Snowball That Touches Off Avalanche?
At the Keystone conference, researchers presented new data to argue that pyroglutamate (pGlu) derivatives of Aβ may be critically important in the underlying pathology of AD...
Keystone: BACE, Age, Stress, Energy—Is Translation to Blame?
At the Alzheimer’s Disease conference, Robert Vassar briefed the audience on his group’s latest work on the β-secretase BACE1...